CD274 and hepatocellular carcinoma: Moreover, PD-1/PD-L1 inhibitors are expensive; despite the promising efficacy demonstrated by the combination of atezolizumab plus bevacizumab in previous studies for first-line treatment of unresectable or advanced HCC, this regimen was hardly economical for HCC patients both in China and the US (Hou and Wu, 2020; Patel et al., 2021).